The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia
Copyright © 2024 Elsevier Ltd. All rights reserved..
PURPOSE: To provide information about which pneumococcal vaccine could have greater coverage in Colombia.
METHODS: This is a retrospective analysis of patients diagnosed with invasive pneumococcal disease (IPD) between 2015 and 2019 in Bogotá, Colombia. We compared the theoretical serotype coverage of the available anti-pneumococcal vaccines (i.e., PCV-10, PCV-10 SII, PCV-13, PCV-15, PCV-20, PCV-21, PCV24, PPSV-23) and the non-vaccine-covered serotypes stratified by age.
RESULTS: 690 IPD cases were included. In children ≤5 y/o, of the approved vaccines PCV-20 showed the most theoretical protection (71.3 % [149/209]), while in adults aged 18-64 y/o was PCV-20 (61.8 % [164/265]), and in those ≥65 y/o was PPSV-23 (58.1 % [100/172]) followed by PCV-20 (55.2 % [95/172]). The non-covered serotypes represented one-third of the cohort (33.9 % [234/690]), being 6C (20.5 % [48/234]), 15A (12.8 % [30/234]), and 23A (11.5 % [27/234]) the most prevalent.
CONCLUSION: Introducing PCV-20 for children and PCV-20 along with a PPSV-23 booster in adults may reduce IPD frequency in all ages in Colombia. The inclusion of non-covered serotypes is required for future vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Vaccine - 42(2024), 7 vom: 07. März, Seite 1435-1439 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Serrano-Mayorga, Cristian C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Invasive pneumococcal disease |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2024.01.086 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368260488 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368260488 | ||
| 003 | DE-627 | ||
| 005 | 20240318234244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2024.01.086 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM368260488 | ||
| 035 | |a (NLM)38336559 | ||
| 035 | |a (PII)S0264-410X(24)00109-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Serrano-Mayorga, Cristian C |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a PURPOSE: To provide information about which pneumococcal vaccine could have greater coverage in Colombia | ||
| 520 | |a METHODS: This is a retrospective analysis of patients diagnosed with invasive pneumococcal disease (IPD) between 2015 and 2019 in Bogotá, Colombia. We compared the theoretical serotype coverage of the available anti-pneumococcal vaccines (i.e., PCV-10, PCV-10 SII, PCV-13, PCV-15, PCV-20, PCV-21, PCV24, PPSV-23) and the non-vaccine-covered serotypes stratified by age | ||
| 520 | |a RESULTS: 690 IPD cases were included. In children ≤5 y/o, of the approved vaccines PCV-20 showed the most theoretical protection (71.3 % [149/209]), while in adults aged 18-64 y/o was PCV-20 (61.8 % [164/265]), and in those ≥65 y/o was PPSV-23 (58.1 % [100/172]) followed by PCV-20 (55.2 % [95/172]). The non-covered serotypes represented one-third of the cohort (33.9 % [234/690]), being 6C (20.5 % [48/234]), 15A (12.8 % [30/234]), and 23A (11.5 % [27/234]) the most prevalent | ||
| 520 | |a CONCLUSION: Introducing PCV-20 for children and PCV-20 along with a PPSV-23 booster in adults may reduce IPD frequency in all ages in Colombia. The inclusion of non-covered serotypes is required for future vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Invasive pneumococcal disease | |
| 650 | 4 | |a PCV-20 | |
| 650 | 4 | |a PPSV-23 | |
| 650 | 4 | |a Pneumococcal vaccination | |
| 650 | 4 | |a Streptococcus pneumoniae | |
| 650 | 7 | |a Vaccines, Conjugate |2 NLM | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 700 | 1 | |a Ibáñez-Prada, Elsa D |e verfasserin |4 aut | |
| 700 | 1 | |a Restrepo-Martínez, Juan M |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Gallo, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Duque, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Severiche-Bueno, David Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Severiche-Bueno, Diego Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas, Hernán |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Luis Felipe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 42(2024), 7 vom: 07. März, Seite 1435-1439 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:7 |g day:07 |g month:03 |g pages:1435-1439 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2024.01.086 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 7 |b 07 |c 03 |h 1435-1439 | ||